Summary of opinion: Imfinzi, 29/01/2026 Positive
Summary of opinion: Imfinzi, 29/01/2026 Positive
Summary of opinion: Imfinzi, 29/01/2026 Positive
Human medicines European public assessment report (EPAR): Scenesse, afamelanotide, Date of authorisation: 22/12/2014, Revision: 13, Status: Authorised
Human medicines European public assessment report (EPAR): Trulicity, dulaglutide, Date of authorisation: 21/11/2014, Revision: 21, Status: Authorised
First immunotherapy-based treatment recommended for advanced anal cancer
List of centrally authorised products with safety-related changes to the product information
Human medicines European public assessment report (EPAR): Qdenga, dengue tetravalent vaccine (live, attenuated), Date of authorisation: 05/12/2022, Revision: 6, Status: Authorised
Final programming document 2026-28
List of industry subject matter experts and list of planned calls for industry subject matter experts
EMEA-002109-PIP01-16
EMEA-002828-PIP01-20